CNR1 and Hepatitis: Finally, the synthetic atypical cannabinoid Abn-CBD, a CBD derivative that does not target the canonical cannabinoid receptors CB1R and CB2R, was recently shown to exert hepatoprotective properties by lowering hepatic fibrosis, liver inflammation, and inflammatory-cell infiltration in the liver, as well as by reducing systemic inflammation and oxidative stress [42].